Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 31
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza García, María Isabel
  • Brea Floriani, José Manuel
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Proinsulin protects against age-related cognitive loss through anti-inflammatory convergent pathways

  • Corpas, Rubén
  • Hernández-Pinto, Alberto M.
  • Porquet, David
  • Hernández-Sánchez, Catalina
  • Bosch, Fátima
  • Comellas, Francesc
  • De la Rosa, Enrique J.
  • Sanfeliu, Coral
40 p.-5 fig., Brain inflammaging is increasingly considered as contributing to age-related cognitive loss and neurodegeneration. Despite intensive research in multiple models, no clinically effective pharmacological treatment has been found yet. Here, in the mouse model of brain senescence SAMP8, we tested the effects of proinsulin, a promising neuroprotective agent that was previously proven to be effective in mouse models of retinal neurodegeneration. Proinsulin is the precursor of the hormone insulin but also upholds developmental physiological effects, particularly as a survival factor for neural cells. Adeno-associated viral vectors of serotype 1 bearing the human proinsulin gene were administered intramuscularly to obtain a sustained release of proinsulin into the blood stream, which was able to reach the target area of the hippocampus. SAMP8 mice and the control strain SAMR1 were treated at 1 month of age. At 6 months, behavioral testing exhibited cognitive loss in SAMP8 mice treated with the null vector. Remarkably, the cognitive performance achieved in spatial and recognition tasks by SAMP8 mice treated with proinsulin was similar to that of SAMR1 mice. In the hippocampus, proinsulin induced the activation of neuroprotective pathways and the downstream signaling cascade, leading to the decrease of neuroinflammatory markers. Furthermore, the decrease of astrocyte reactivity was a central effect, as demonstrated in the connectome network of changes induced by proinsulin. Therefore, the neuroprotective effects of human proinsulin unveil a new pharmacological potential therapy in the fight against cognitive loss in the elderly., This work was supported by grants: CSD2010-00045 to CS and EJdlR, from the Spanish Ministerio de Economía y Competitividad (MINECO), SAF2016-77703-C2-2-R to CS and MTM2014-60127-P to FC from MINECO and European Regional Development Fund (ERDF), and TRACE (PET08-0282) to FB and EJdlR, from the Spanish Ministerio de Ciencia e Innovación (MICINN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol modulates response against acute inflammatory stimuli in aged mouse brain

  • Palomera-Ávalos, Verónica
  • Griñán-Ferré, Christian
  • Izquierdo, Vanesa
  • Camins, Antoni
  • Sanfeliu, Coral
  • Canudas, Anna Maria
  • Pallàs, Mercè
With upcoming age, the capability to fight against harmful stimuli decreases and the organism becomes more susceptible to infections and diseases. Here, the objective was to demonstrate the effect of dietary resveratrol in aged mice in potentiating brain defenses against LipoPolySaccharide (LPS). Acute LPS injection induced a strong proinflammatory effect in 24-months-old C57/BL6 mice hippocampi, increasing InterLeukin (Il)-6, Tumor Necrosis Factor-alpha (Tnf-α), Il-1β, and C-X-C motif chemokine (Cxcl10) gene expression levels. Resveratrol induced higher expression in those cytokines regarding to LPS. Oxidative Stress (OS) markers showed not significant changes after LPS or resveratrol, although for resveratrol treated groups a slight increment in most of the parameters studies was observed, reaching signification for NF-kB protein levels and iNOS expression. However, Endoplasmic Reticulum (ER) stress markers demonstrated significant changes in resveratrol-treated mice after LPS treatment, specifically in eIF2α, BIP, and ATF4. Moreover, as described, resveratrol is able to inhibit the mechanistic Target of Rapamycin (mTOR) pathway and this effect could be linked to (eIF2α) phosphorylation and the increase in the expression of the previously mentioned proinflammatory genes as a response to LPS treatment in aged animals. In conclusion, resveratrol treatment induced a different cellular response in aged animals when they encountered acute inflammatory stimuli., This study was supported by Spanish MINECO (SAF2016-77703, CSD2010-00045), and the European Regional Development Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Understanding epigenetics in the neurodegeneration of alzheimer’s disease: SAMP8 mouse model

  • Griñán-Ferré, Christian
  • Corpas, Rubén
  • Puigoriol-Illamola, Dolors
  • Palomera-Ávalos, Verónica
  • Sanfeliu, Coral
  • Pallàs, Mercè
Epigenetics is emerging as the missing link among genetic inheritance, environmental influences, and body and brain health status. In the brain, specific changes in nucleic acids or their associated proteins in neurons and glial cells might imprint differential patterns of gene activation that will favor either cognitive enhancement or cognitive loss for more than one generation. Furthermore, derangement of age-related epigenetic signaling is appearing as a significant risk factor for illnesses of aging, including neurodegeneration and Alzheimer’s disease (AD). In addition, better knowledge of epigenetic mechanisms might provide hints and clues in the triggering and progression of AD. Intense research in experimental models suggests that molecular interventions for modulating epigenetic mechanisms might have therapeutic applications to promote cognitive maintenance through an advanced age. The SAMP8 mouse is a senescence model with AD traits in which the study of epigenetic alterations may unveil epigenetic therapies against the AD., This study was supported by Spanish MINECO (SAF2016-77703, CSD2010-00045), and the European Regional Development Funds, and 2017-SGR106 and the CERCA Programme from the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Melatonin induces mechanisms of brain resilience against neurodegeneration.

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Palomera-Ávalos, Verónica
  • Porquet, David
  • García de Frutos, Pablo
  • Franciscato Cozzolino, Silvia M.
  • Rodríguez-Farré, Eduard
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Cardoso, Bárbara R.
Melatonin is an endogenous pleiotropic molecule which orchestrates regulatory functions and protective capacity against age‐related ailments. The increase in circulating levels of melatonin through dietary supplements intensifies its health benefits. Investigations in animal models have shown that melatonin protects against Alzheimer's disease (AD)‐like pathology, although clinical studies have not been conclusive. We hypothesized that melatonin induces changes in the brain that prevent or attenuate AD by increasing resilience. Therefore, we treated healthy nontransgenic (NoTg) and AD transgenic (3xTg‐AD) 6‐month‐old mice with a daily dose of 10 mg/kg of melatonin until 12 months of age. As expected, melatonin reversed cognitive impairment and dementia‐associated behaviors of anxiety and apathy and reduced amyloid and tau burden in 3xTg‐AD mice. Remarkably, melatonin induced cognitive enhancement and higher wellness level‐related behavior in NoTg mice. At the mechanism level, NF‐κB and proinflammatory cytokine expressions were decreased in both NoTg and 3xTg‐AD mice. The SIRT1 pathway of longevity and neuroprotection was also activated in both mouse strains after melatonin dosing. Furthermore, we explored new mechanisms and pathways not previously associated with melatonin treatment such as the ubiquitin‐proteasome proteolytic system and the recently proposed neuroprotective Gas6/TAM pathway. The upregulation of proteasome activity and the modulation of Gas6 and its receptors by melatonin were similarly displayed by both NoTg and 3xTg‐AD mice. Therefore, these results confirm the potential of melatonin treatment against AD pathology, by way of opening new pathways in its mechanisms of action, and demonstrating that melatonin induces cognitive enhancement and brain resilience against neurodegenerative processes., This study was supported by grants SAF2016‐77703‐R, SAF2015‐66515‐R and SAF2016‐81716‐REDC from Spanish MINECO and European Development Fund, and 2017‐SGR‐106 from AGAUR and the CERCA Programme of the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neurotransmitter amines and antioxidant agents in neuronal protection against methylmercury-induced cytotoxicity in primary cultures of mice cortical neurons

  • Olguín, Nair
  • Müller, Marie-Lena
  • Rodríguez-Farré, Eduard
  • Suñol, Cristina
Methylmercury (MeHg) is an environmental toxicant with detrimental effects on the developing brain and adult nervous system. The main mechanisms identified include oxidative stress, changes in intracellular calcium, mitochondrial changes, inhibition of glutamate uptake, of protein synthesis and disruption of microtubules. However, little is known about mechanisms of protection against MeHg neurotoxicity. We found that resveratrol (10 μM) and ascorbic acid (200 μM) protected MeHg-induced cell death in primary cultures of cortical neurons. In this work, we aimed at finding additional targets that may be related to MeHg mode of action in cell toxicity with special emphasis in cell protection. We wonder whether neurotransmitters may affect the MeHg effects on neuronal death. Our findings show that neurons exposed to low MeHg concentrations exhibit less mortality if co-exposed to 10 μM dopamine (DA). However, DA metabolites, HVA (homovanillic acid) and DOPAC (3,4-dihydroxyphenylacetic acid) are not responsible for such protection. Furthermore, both DA D1 and D2 receptors agonists showed a protective effect against MeHg toxicity. It is striking though that DA receptor antagonists SKF83566 (10 μM) and haloperidol (10 μM) did not inhibit DA protection against MeHg. In addition, the protective effect of 10 μM DA against MeHg-induced toxicity was not affected by additional organochlorine pollutants exposure. Our results also demonstrate that cells exposed to MeHg in presence of 100 μM acetylcholine (ACh), show an increase in cell mortality at the “threshold value” of 100 nM MeHg. Finally, norepinephrine (10 μM) and serotonin (20 μM) also had an effect on cell protection. Altogether, we propose to further investigate the additional mechanisms that may be playing an important role in MeHg-induced cytotoxicity., This research was supported by the Spanish projects PI13/01252 and PI15/00033 from the Instituto de Salud Carlos III and SAF2016-77703-C2-2-R from MINECO, cofinanced with European Social Funds “A Way to build Europe”, and the 2017/SGR/106 and CERCA Programme from the Generalitat of Catalunya. N.O. is recipient of a CSIC JAE-Doc contract from the “Junta para la Ampliación de Estudios” Program cofinanced with European Social Funds, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders

  • Zeinolabediny, Yasmin
  • Caccuri, Francesca
  • Colombo, Laura
  • Morelli, Federica
  • Romeo, Margherita
  • Rossi, Alessandro
  • Schiarea, Silvia
  • Ciaramelli, Carlotta
  • Airoldi, Cristina
  • Weston, Ria
  • Donghui, Liu
  • Krupinski, Jerzy
  • Corpas, Rubén
  • García-Lara, Elisa
  • Sarroca, Sara
  • Sanfeliu, Coral
  • Slevin, Mark
  • Caruso, Arnaldo
  • Salmona, Mario
  • Diomede, Luisa
Human immunodeficiency virus type-1 (HIV-1)-associated neurocognitive disorder (HAND) remains an important neurological manifestation that adversely affects a patient’s quality of life. HIV-1 matrix protein p17 (p17) has been detected in autoptic brain tissue of HAND individuals who presented early with severe AIDS encephalopathy. We hypothesised that the ability of p17 to misfold may result in the generation of toxic assemblies in the brain and may be relevant for HAND pathogenesis. A multidisciplinary integrated approach has been applied to determine the ability of p17 to form soluble amyloidogenic assemblies in vitro. To provide new information into the potential pathogenic role of soluble p17 species in HAND, their toxicological capability was evaluated in vivo. In C. elegans, capable of recognising toxic assemblies of amyloidogenic proteins, p17 induces a specific toxic effect which can be counteracted by tetracyclines, drugs able to hinder the formation of large oligomers and consequently amyloid fibrils. The intrahippocampal injection of p17 in mice reduces their cognitive function and induces behavioral deficiencies. These findings offer a new way of thinking about the possible cause of neurodegeneration in HIV-1-seropositive patients, which engages the ability of p17 to form soluble toxic assemblies., Tis work was partially supported by Banca Intesa Sanpaolo, 2016- 2017, Fondazione Sacchetti 2016-2017, Spanish MINECO grant SAF2016-77703 and European Development Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Anti-aging mechanisms may prevent development of Alzheimer's disease

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
Trabajo presentado en el XI Simposi de Neurobiologia: Future technical advances, organizado por la Socitat Catalana de Biologia, en Barcelona, los días 12 y 13 de noviembre de 2018, The progressive increase in life expectancy has led to an increase in the incidence of age-related diseases, including Alzheimer’s disease (AD). Currently there are no effective treatments against AD, therefore, the search for preventive treatments is of great interest to achieve healthy aging. We hypothesize that the activation of anti-aging molecular pathways may induce a preventive effect of cellular resilience against the development of AD pathological processes. We evaluated the proposed anti-aging compounds resveratrol and melatonin by diet supplementation in 3xTgAD and control healthy NoTg mice. Both compounds activated the neuroprotective and longevity SIRT1 pathway. The changes in 3xTg-AD hippocampus included decline of Aβ and tau pathology, decrease of inflammatory markers that suggests a protection against inflammaging, increase of proteolytic mechanism against aberrant proteins, and beneficial changes in mitochondrial function and plasticity processes. Remarkably, these treatments induced upregulation of neuroprotective mechanisms in the healthy NoTg mice. Both resveratrol and melatonin protected against memory loss in 3xTg-AD and induced improved behavior in the healthy mice. Our data confirmed the potential of both anti-aging compounds to induce neuroprotection against AD-pathology, and unveiled their preventive effects by increasing brain resilience, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Monomeric C reactive protein induces signaling pathsways leaading to dementia in mice

  • García-Lara, Elisa
  • Corpas, Rubén
  • Slevin, Mark
  • Sanfeliu, Coral
Trabajo presentado en el XI Simposi de Neurobiologia: Future technical advances, organizado por la Socitat Catalana de Biologia, en Barcelona, los días 12 y 13 de noviembre de 2018, There is strong evidence that brain ischaemic processes increase the risk of suffering age-related dementia. Stroke may induce the development of vascular dementia, but also of Alzheimer’s disease (AD) which is the leading cause of dementia worldwide. Neuroinflammation derived from ischaemic damage in the vessels and brain paremchima may be the causative of neurodegeneration. We have previously demonstrated that the monomeric C- reactive protein (mCRP) may provide a causative link between stroke-associated inflammation and dementia, as its injection into the hippocampus of wild type mice induced loss of memory within one month period [Slevin et al., 2015; Sci Rep 5:13281]. mCRP is a monomeric protein that comes from the dissociation of the pentraxin C-reactive protein (CRP) that remain chronically within the extracellular matrix of ischaemic tissue after stroke. Here we reproduced the mouse model of dementia by mCRP and extended the period post injection up to 6 months to further characterize the mCRP effects on cognition and general behavior. Mice of the transgenic AD strain 5XFAD were also tested for comparison. Treatment with mCRP induced lack of learning and memory at one, three and six months after bilateral injection into the hippocampus of the mice. We assayed the hippocampus tissue for gene expression and protein levels in a search of changes underlying cognitive loss and neurodegeneration. First results revealed lower activation of signaling pathways related to Arc and Egr1 early genes in mCRP mice but not in 5XFAD mice. Main changes in 5XFAD were related to oxidative stress and gliosis markers. We will pursue the molecular study to discern differential patterns between mCRP and 5XFAD mice. Characterizing the mechanisms of mCRP-induced dementia might contribute to decrease AD incidence in the elderly., EU-COP 2014-2020, CRP-SAD, ID: P_37_674, MySMIS code: 103432, contract: 51/05.09.2016; SAF2016‐77703, MINECO and ERDF; 2017-SGR-106, AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Resveratrol upregulates the expression of antioxidant genes inimmortalized AD lymphocytes

  • Senserrich, Júlia
  • Cosín-Tomás, Marta
  • Martín Requero, A.
  • Pallàs, Mercè
  • Kaliman, Perla
  • Sanfeliu, Coral
Trabajo presentado en el XI Simposi de Neurobiologia: Future technical advances, organizado por la Socitat Catalana de Biologia, en Barcelona, los días 12 y 13 de noviembre de 2018, Alzheimer’s disease (AD) is the most common neurodegenerative disorder and first cause of dementia all over the world. It is characterized by a progressive neuronal loss. The main risk factor for developing AD is the age. Major pathological hallmarks include extracellular deposits of amyloid protein and intracellular deposits of neurofibrillary tau protein. AD brain also shows alterations developed in aged brain such as oxidative stress and inflammation. The study used immortalized lymphocytes from patients of sporadic AD and age-matched healthy controls (HC) with the following aims: First, analyze gene expression of oxidative stress and aging-related pathways in AD and HC lymphoblast cell lines. Next, investigate the potential role of resveratrol as antiaging and protective agent through the induction of further gene expression changes. Finally, establish the different sensitivity between the human immortalized lymphocyte cell lines and the human neuroblastoma cell line SH-SY5Y to the hormetic agent resveratrol and to oxidative stress inductors. Real-time PCR showed that oxidative stress and aging-related genes were differentially expressed in AD lymphoblasts compared to HC lymphoblasts with increases in CASP1, TXNIP, VPS13C, GPX1, PRDX5, SOD2, and decrease in CCS expression. Resveratrol incubated for 18h at concentration of 10, 20 or 50µM induced a general upregulation of antioxidant and detoxifying genes such as: CAT, NFE2L2, GSTZ1, and CCS, in both HC and AD lymphoblasts. Resveratrol also induced the expression of the anti-aging mitochondrial sirtuin SIRT3. At the concentrations tested, resveratrol was not cytotoxic to lymphoblast or SH-SY5Y neuroblastoma cultures, although the later were more sensitive to oxidative injuries. This study supports that immortalized lymphocytes is a suitable cell system to analyze molecular alterations of pathways common to non-neural and neural cells. Furthermore, resveratrol upregulation of antioxidant genes may contribute to improve physiological processes in aging and AD., Supprted by grants: SAF2016‐77703, MINECO and ERDF; 2017-SGR-106, AGAUR, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Modulation of the enzyme soluble epoxide hydrolase as a therapeutic target against neurodegenerative diseases

  • Almenara-Fuentes, Lidia
  • Corpas, Rubén
  • Suñol, Cristina
  • Vázquez, S.
  • Galdeano, Carles
  • Pallàs, Mercè
  • Sanfeliu, Coral
Trabajo presentado en el XI Simposi de Neurobiologia: Future technical advances, organizado por la Socitat Catalana de Biologia, en Barcelona, los días 12 y 13 de noviembre de 2018, Neurodegenerative diseases cursing with chronic inflammatory conditions represent a major health problem due to the global increase in life expectancy and age-related diseases. Thus, there is an urgent need for new approaches to mitigate neuroinflammation. Epoxyeicosatrienoic acids (EETs) are endogenous mediators that have several potentially protective functions including anti-inflammatory effects. EETs beneficial effects disappear when the enzyme soluble Epoxide Hydrolase (sEH) metabolizes them to the corresponding dihydroxyeicosatrienoic acids. Therefore, sEH enzyme is emerging as a promising pharmacological target, because its inhibition allows increasing EETs and keeping them active. The aim of the present study was to determine the half maximal inhibitory concentration (IC50) of a newly synthetized sEH inhibitor (sEHi) series, agents A01, A02, A03, A04, A05 and A06, and study their toxicity and anti-inflammatory effects. Neuroblastoma SH-SY5Y cell cultures were used to the IC50 calculation and the safety level of each sEHi. To study the anti-inflammatory effects, lipopolysaccharide stimulated microglial-like BV2 cells were used to obtain conditioned media with the proinflammatory mediators. Modulatory effects on the inflammatory pathways iNOS and NFĸB, and the release of cytokines were explored using techniques of Western Blot, immunocytochemistry and ELISA. All agents showed higher inhibitory potency than the reference compound 1-(1-propionylpiperidin-4-yl)- 3-[4-(trifluoromethoxy)phenyl]urea (TPPU) and generally low cytotoxicity. They also showed promising anti-inflammatory properties. In this way, the newly synthesized sEHi agents could be a new therapy against the neuroinflammation present in neurodegenerative diseases as Alzheimer’s disease, and in other neurological diseases with an inflammatory component., Supported by: SAF2016‐77703, MINECO and ERDF; 2017-SGR-106 AGAUR, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Proinsulin therapy protects against neuroinflammaging and cognitive loss in senescence-accelerated mice

  • Sanfeliu, Coral
  • Corpas, Rubén
  • Hernández-Pinto, Alberto M.
  • Porquet, David
  • Hernández-Sánchez, Catalina
  • Bosch, Fátima
  • Ortega-Aznar, Arantxa
  • Comellas, Francesc
  • De la Rosa, Enrique J.
Trabajo presentado en el IUBMB Focused Meeting on «Molecular aspects of aging and longevity», celebrado en Atenas, del 16 al 19 de octubre de 2017, Chronic low-grade neuroinflammation is tightly associated with brain age-related changes and it is considered a crucial derangement that paves the way to neurodegeneration and dementia. Among other ailments, inflammation may lead to insulin resistance that is a risk factor for Alzheimer’s disease. In this scenario, the hormone precursor proinsulin may have a potential pharmacological use in preventing neuronal death. Proinsulin is a bioactive molecule regulating neural cell death in embryonic processes and it was proven neuroprotective in mouse models of retinal neurodegeneration. We aimed to prove the geroprotective effect of a chronic proinsulin treatment against neuroinflammaging and memory loss in the senescence-accelerated mouse SAMP8. We used a gene therapy procedure through peripheral muscle transduction with an adeno-associated viral vector bearing the human proinsulin gene (AAV-hPi) that yielded sustained release of proinsulin into the bloodstream. One-month old male mice of the SAMP8 strain and the control strain SAMR1 were injected with AAV-hPi or AAV-null vectors. At 6 months of age, proinsulin-treated SAMP8 mice showed totally preserved cognitive capacities both in spatial and recognition paradigms of learning and memory, in contrast to those SAMP8 mice injected with the null vector. Hippocampus analysis showed that proinsulin activated Akt and ATF1/CREB signaling pathways in both SAMR1 and SAMP8 mice. Furthermore, we identified a significant decrease of neuroinflammatory markers in the hippocampus of SAMP8 mice to levels of SAMR1 mice. Strikingly, the marker of astrocyte reactivity GFAP was decreased in both SAMR1 and SAMP8. Furthermore, the connectome network build with all changes induced by proinsulin showed that the decrease of astrocyte reactivity was a central effect in proinsulin neuroprotection. Therefore, the preventive and protective effects of human proinsulin against neuroinflammaging and senescence-related cognitive loss unveil a potential geroprotective therapy to increase healthy brain aging., This study was supported by CSD2010-00045, SAF2016-77703-C2-2-R, MTM2014-60127-P, MINECO and ERDF; PET08-0282, TRACE., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Resveratrol induces resilience against age-related neurodegeneration through improvement of proteostasis

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
Trabajo presentado en el IUBMB Focused Meeting on «Molecular aspects of aging and longevity», celebrado en Atenas, del 16 al 19 de octubre de 2017, Resveratrol is a natural compound that mimics the antiaging effect of caloric restriction, which is mainly mediated through SIRT1, a NAD+-dependent deacetylase that induces longevity and neuroprotection by regulating the acetylation homeostasis of key proteins. Resveratrol is a potential preventive agent against age-related neurodegeneration and was proven to protect against Alzheimer’s disease (AD)-like pathology in experimental models. In this study, we aimed to analyze the effects of resveratrol on the brain status of control non-transgenic (NoTg) mice and AD transgenic mice to discern the mechanisms involved in a potential inducement of resilience against age-related neurodegeneration and AD. NoTg and 3xTg-AD mice were fed with a diet supplemented with trans-resveratrol, at 100 mg/kg during 10 month. The period of 2 to 12 months of age covered a broad period of the AD pathology progression, from the pre-symptomatic to the advanced AD pathology phase. Resveratrol administration induced complete protection against memory loss and brain pathology in 3xTg-AD mice, and also induced cognitive enhancement in NoTg mice. Resveratrol reduced the presence of Aβ and p-tau pathology in the hippocampus of 3xTg-AD mouse. Proteostasis analysis showed in both healthy and AD mice: (i) increased levels of the amyloid degrading enzyme Neprilysin; (ii) increase of protein proteasome levels and activity; (iii) reduction of the amyloidogenic secretase BACE1. Resveratrol increased the AMPK protein levels, then upregulating SIRT1 pathway as shown by activation of PGC-1α and CREB in 3xTg-AD and NoTg mice, resulting in further beneficial changes in the mitochondrial function and plasticity processes, respectively. Our data demonstrate that resveratrol induces cognitive enhancement and neuroprotection against amyloid and tau pathologies. Improvement of proteostasis by resveratrol, in both healthy and AD mice, suggests it is a mechanism of brain resilience and defense against neurodegeneration caused by accumulation of aberrant proteins., Supported by SAF2016-77703, MINECO and ERDF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis de maestría (MasterThesis)

Neuroprotective mechanisms of resveratrol in a high-fat diet-fed Alzheimer's disease mouse model

  • Gatius, Alaó
Over the last decades there has been an over consumption of foods rich in animal fats that has led to a global obesity pandemic. Obesity presents itself with a number of comorbidities, including an increased risk for the development of neurodegenerative disorders such as Alzheimer’s disease (AD). On the other hand, reducing caloric intake has showed to delay age-related diseases and resveratrol, a polyphenol produced by a variety of plants, has emerged as a potent mimetic of this caloric restriction. The mechanisms underlying both effects are not fully understood and, as potential therapeutic targets, need to be thoroughly analyzed. To this end, we have analyzed molecular pathways involved in memory loss in mice as a result of a high-fat diet (HFD) administration and the role that resveratrol supplementation on this diet may play. We have focused on 6-months-old 5xFAD mice, which are transgenic AD mice with a high amyloid burden, and wild type (WT) mice. Both mice strains fed with HFD showed impairment of recognition memory but when resveratrol was added to the HFD, recognition memory was restored. Moreover, our results indicate that HFD boosts amyloid pathology in both, WT and 5xFAD mice, mainly through the potentiation of the amyloidogenic pathway and the reduction of the non-amyloidogenic one. Namely, we identified an increase in β-secretase (BACE1) protein levels in both strains and a decrease in α-secretase (ADAM10) expression in WT mice after HFD administration. Tau pathology was as well aggravated in both strains. Interestingly, HFD has showed the capacity to enhance the activity of the ubiquitin-proteasome system, being the most significant changes the induction of proteasome caspase-like and chymotrypsin-like activities. Remarkably, resveratrol has demonstrated the capability to normalize all the pathological changes induced by the HFD in both WT and 5xFAD mice, confirming its preventive and therapeutic potential against neurodegeneration., SAF2016-77703-C2-2-R of the Ministerio de Economía y Competitividad, Spain and the European Regional Development Fund (ERDF); AGAUR 2017-SGR-106 and the CERCA Programme of the Generalitat de Catalunya; R. Copas and C. Sanfeliu belong to Group 05 of CIBER Epidemiología y Salud Pública (CIBERESP) of the Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Spain, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis de maestría (MasterThesis)

Lymphoblasts as potential peripheral biomarkers of Alzheimer's disease and the protective role of resveratrol

  • Senserrich, Júlia
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and first cause of dementia all over the world. It is characterized by a progressive neuronal loss. The main risk factor for developing AD is the age and it is known that there are shared pathological changes between them. Major pathological hallmarks include extracellular deposits of amyloid protein and intracellular deposits of neurofibrillary tau protein. Moreover, it is though that β-amyloid peptide induce cytotoxicity by the generation of reactive oxygen intermediates, contributing to protein tau’s hyperphosphorylation., The study used immortalised lymphocytes from patients of sporadic AD and age-matched healthy controls with following aims: First, use real-time PCR to verify the results of several genes expression analysed by array, in a previous study. Second, investigate the potential role of resveratrol, inducing an upregulation of genes involved in the antioxidant cell response and regulating the aging pathway. Finally, establish the different sensitivity between the human immortalized lymphocyte cell lines and human neuroblastoma cell lines, both treated with resveratrol and hydrogen peroxide (H2O2), an oxidative stress inductor., The current study was observed that gene expression results by PCR did not correlated with those obtained by array, suggesting a variability through individuals. Moreover, aging genes seemed to be more expressed by AD patients, but resveratrol did not induce any effect. Contrary to genes involved in an antioxidant response, which an upregulation induced by resveratrol was clearly demonstrated in most antioxidant genes tested. In addition, it was seen the high toxicity produced by an oxidative stress inductor and the trace that resveratrol 50µM could be the threshold of toxicity for neuronal cells, while lymphoblastomas showed to be more resistant to those compounds., SAF2016-77703-C2-2-R of the Ministerio de Economía y Competitividad, Spain and the European Regional Development Fund (ERDF); AGAUR 2017-SGR106 and the CERCA Programme of the Generalitat de Catalunya; C. Sanfeliu belong to Group 05 of CIBER Epidemiología y Salud Pública (CIBERESP) of the Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Spain, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis de maestría (MasterThesis)

Epoxide Hydrolase enzyme as a therapeutic target against Alzheimer's Disease

  • Almenara-Fuentes, Lidia
Alzheimer’s Disease (AD) represents a serious problem for the population health due to the increase in the life expectancy. Inflammation in AD is widely present and it is considered as a contributor to the cognitive loss and neurodegeneration. Epoxyeicosatrienoic acids (EETs) have anti-inflammatory properties which disappear when the enzyme soluble Epoxide Hydrolase (sEH) metabolizes them to the corresponding dihydroxyeicosatrienoic acids (DHETs). SEH is emerging as a promising pharmacological target because allows the increase of EETs and keep them active. The aim of the present study was to calculate the half maximal inhibitory concentration (IC50) of a newly synthetized sEH inhibitors (UB21, UB23, UB24, UB28, EPB50 and EV52), study their toxicity and the anti-inflammatory effects. SH-SY5Y cell cultures were used to the IC50 calculation and the toxicity of each sEHi. To study the inflammatory effects, lipopolysaccharide (LPS) stimulated microglial, BV2 cells were used to obtain conditioned media with the proinflammatory mediators. Modulation of the inflammatory pathways iNOS and NFĸB, and the release of proinflammatory cytokines were analyzed by techniques of Western Blot, immunocytochemistry and ELISA. All agents showed a higher inhibitory potency than the reference compound 1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), being the IC50 of UB23 and UB28 at nanomolar range. EV52 could not been tested due to their random activity values. All sEHi were not cytotoxic at the anticipated concentrations, except EV52. The preliminary testing of anti-inflammatory effects unveils UB23 as the best candidate, SAF2016-77703-C2-2-R of the Ministerio de Economía y Competitividad, Spain and the European Regional Development Fund (ERDF); AGAUR 2017-SGR-106 and the CERCA Programme of the Generalitat de Catalunya; R. Copas and C. Sanfeliu belong to Group 05 of CIBER Epidemiología y Salud Pública (CIBERESP) of the Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modelling physical resilience in ageing mice

  • Schosserer, Markus
  • Banks, Gareth
  • Dogan, Soner
  • Dungel, Peter
  • Fernandes, Adelaide
  • Marolt Presen, Darja
  • Matheu, Ander
  • Osuchowski, Marcin
  • Potter, Paul
  • Sanfeliu, Coral
  • Guvenc Tuna, Bilge
  • Varela-Nieto, Isabel
  • Bellantuono, Ilaria
Geroprotectors, a class of drugs targeting multiple deficits occurring with age, necessitate the development of new animal models to test their efficacy. The COST Action MouseAGE is a European network whose aim is to reach consensus on the translational path required for geroprotectors, interventions targeting the biology of ageing. In our previous work we identified frailty and loss of resilience as a potential target for geroprotectors. Frailty is the result of an accumulation of deficits, which occurs with age and reduces the ability to respond to adverse events (physical resilience). Modelling frailty and physical resilience in mice is challenging for many reasons. There is no consensus on the precise definition of frailty and resilience in patients or on how best to measure it. This makes it difficult to evaluate available mouse models. In addition, the characterization of those models is poor. Here we review potential models of physical resilience, focusing on those where there is some evidence that the administration of acute stressors requires integrative responses involving multiple tissues and where aged mice showed a delayed recovery or a worse outcome then young mice in response to the stressor. These models include sepsis, trauma, drug- and radiation exposure, kidney and brain ischemia, exposure to noise, heat and cold shock., This article is based upon work from COST Action (BM1402: MouseAGE), supported by COST (European Cooperation in Science and Technology) and European Union Research and Innovation Program Horizon 2020 (GrantAgreement Number 730879). This work was supported by the Austrian Research Fund (FWF: P30623-B26), the Spanish MINECO (SAF2016-77703), the European Regional Development Fund, and the MRC-Arthritis Research UK Centre for Integrated Research into Musculoskeletal Ageing., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peripheral Maintenance of the Axis SIRT1-SIRT3 at Youth Level May Contribute to Brain Resilience in Middle-Aged Amateur Rugby Players

  • Corpas, Rubén
  • Solana, Elisabeth
  • Rosa, Adrián de la
  • Sarroca, Sara
  • Griñán-Ferré, Christian
  • Oriol, Mireia
  • Corbella, Emili
  • Rodríguez-Farré, Eduard
  • Vina, Jose
  • Pallàs, Mercè
  • Bartrés-Faz, David
  • Gómez-Cabrera, M. C.
  • Sanfeliu, Coral
Physical exercise performed regularly is known to improve health and to reduce the risk of age-related diseases. Furthermore, there is some evidence of cognitive improvement in physically active middle-aged and older adults. We hypothesized that long-term physically active middle-aged men may have developed brain resilience that can be detected with the analysis of peripheral blood markers. We aimed to analyze the activation of pathways potentially modulated by physical activity in a cohort of healthy amateur rugby players (n = 24) and control subjects with low physical activity (n = 25) aged 45¿65 years. We had previously reported neuropsychological improvement in immediate memory responses in the player group compared to the controls. Here, we tested the expression of selected genes of longevity, inflammation, redox homeostasis, and trophic signaling in whole blood mRNA. Analyses were also performed on blood samples of young (aged 15¿25 years) control subjects with low physical activity (n = 21). Physical activity and other lifestyle factors were thoroughly recorded with standardized questionnaires. Interestingly, middle-aged control subjects showed lower levels of expression of SIRT1, SIRT3, CAT, and SOD1 than the young controls, although rugby players maintained the expression levels of these genes at a young-like level. Middle-aged players showed lower levels of IL1B than the non-physically active groups. However, there was a tendency towards a decrease in trophic and transduction factors in middle-aged groups as compared to the young controls. A statistical study of Spearman¿s correlations supported a positive effect of sporting activity on memory and executive functions, and on peripheral gene expression of SIRT1, SIRT3 and downstream genes, in the middle-aged rugby players. Our results indicate that the SIRT1-SIRT3 axis, and associated neuroprotective signaling, may contribute to the anti-aging resilience of the brain mediated by physical exercise., This work was supported by the following grants: Ajut Mario Sàlvia i Ferret 2014 de l’Institut d’Estudis Catalans (IEC), Barcelona, ‘‘Per Incentivar la Recerca en Biomedicina i Estil de Vida’’ (Grant to Incentivize the Research in Biomedicine and Lifestyles); SAF2016-77703 from the Spanish MINECO (Ministerio de Economía y Competitividad) and FEDER.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Rodríguez-Farré, Eduard
  • Pallàs, Mercè
  • Sanfeliu, Coral
Resveratrol is a natural compound that mimics the antioxidant and antiaging effects of caloric restriction, mainly mediated through SIRT1, a deacetylase that induces longevity and neuroprotection. We aimed to analyze the effects of resveratrol on the brain status of control non-transgenic (NoTg) and AD transgenic (3xTg-AD) mice to discern the mechanisms involved in a potential inducement of resilience against age-related neurodegeneration and Alzheimer’s disease (AD). Mice were fed with a diet supplemented with 100 mg/kg of resveratrol from 2 months of age during 10 months. Resveratrol administration induced complete protection against memory loss and brain pathology in 3xTg-AD mice, and also induced cognitive enhancement in healthy NoTg mice. Resveratrol improved exploration and reduced anxiety in both mouse strains, indicative of well-being. Resveratrol reduced the presence of Aβ and p-tau pathology in the hippocampus of the 3xTg-AD mouse. Proteostasis analysis showed the following in both NoTg and 3xTg-AD mice: (i) increased levels of the amyloid-degrading enzyme neprilysin, (ii) reduction of the amyloidogenic secretase BACE1, and (iii) increase of proteasome protein levels and enhancement of proteasome activity. Resveratrol also increased AMPK protein levels, then upregulating the SIRT1 pathway, as shown by the activation of PGC-1α and CREB in both mice, resulting in further beneficial changes. Our data demonstrated that resveratrol induces cognitive enhancement and neuroprotection against amyloid and tau pathologies. Improvement of proteostasis by resveratrol, in both healthy and AD mice, suggests that it is a mechanism of brain resilience and defense against neurodegeneration caused by the accumulation of aberrant proteins., This study was supported by grants SAF2016-77703 and SAF2016-81716-REDC from Spanish MINECO and European Development Fund; 2017-SGR-106 from AGAUR and the CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Long-term physical activity induces brain resilience in middle-aged adults

  • Corpas, Rubén
  • Solana, Elisabeth
  • Rosa, Adrián de la
  • Sarroca, Sara
  • Griñán-Ferré, Christian
  • Oriol, Mireia
  • Corbella, Emili
  • Rodríguez-Farré, Eduard
  • Vina, Jose
  • Pallàs, Mercè
  • Bartrés-Faz, David
  • Gómez-Cabrera, M. C.
  • Sanfeliu, Coral
Trabajo presentado en la Jornada Científica CIBERESP (Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública), celebrada en Madrid (España), el 14 de noviembre de 2019, AIM: Physical activity practiced regularly is known to improve the well-being and to reduce the risk of age-related diseases. We aimed to determine the impact of long-term physical activity on memory maintenance and search for peripheral blood markers related to cognitive function that may be detectable at middle-age METHODS: We performed neuropsychological analyses to veteran amateur rugby players (n = 24, age: 46–68 y) and middleaged sedentary controls (n = 25, age: 47–67 y). We analyzed the expression of selected genes in whole blood mRNA of player and control groups and young sedentary controls (n = 21, age: 17–25 y). A young trained group (n = 16, age: 18–25 y) was added to analyze age-related response in circulating neurotrophins induced by chronic exercise, Ajut Mario Sàlvia i Ferret 2014, lnstitut d'Estudis Catalans; SAF2016‐77703, MINECO and ERDF; 2017-SGR-106, AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Long-term sport practice induces brain resilience through SIRT1-SIRT3 axis in male veteran rugby players

  • Sanfeliu, Coral
  • Corpas, Rubén
  • Solana, Elisabeth
  • Rosa, Adrián de la
  • Sarroca, Sara
  • Griñán-Ferré, Christian
  • Oriol, Mireia
  • Corbella, Emili
  • Rodríguez-Farré, Eduard
  • Vina, Jose
  • Pallàs, Mercè
  • Bartrés-Faz, David
  • Gómez-Cabrera, M. C.
Trabajo presentado en el FENS Regional Meeting, celebrado en Belgrado (Sebia), del 10 al 13 de julio de 2019, Aim: Physical exercise performed regularly is known to improve health and to reduce the risk of age-related diseases. We had previously reported improved immediate memory responses in a cohort of veteran rugby players as compared to control subjects with low physical activity. We hypothesized that long-term physically active middle-aged men have developed brain resilience that can be detected with the analysis of peripheral blood markers. Methods: We tested the expression of selected genes of longevity, inflammation, redox homeostasis, and trophic signaling in whole blood mRNA. Analyses were performed on blood samples of veteran rugby players (n=24) and controls (n=25) aged 45-65 year, and also young controls (aged 15-25 years) with low physical activity (n=21). Physical activity and other lifestyles were thoroughly recorded with standardized questionnaires. Results: Middle-aged control subjects showed lower levels of expression of SIRT1, SIRT3 and CAT than the young controls, although rugby players maintained the expression levels of these genes at a young-like level. No differences were detected in the inflammatory genes, although there was a tendency towards a decrease in trophic and transduction factors in middle-aged groups as compared to the young controls. A statistical study of Spearman’s correlations supported a positive effect of sporting activity on memory and executive functions through SIRT1, SIRT3 and antioxidant gene expression levels in the veteran rugby players. Conclusions: Our results suggest the involvement of the SIRT1-SIRT3 axis, and the downstream antioxidant and neuroprotective signaling, in the anti-aging resilience of the brain mediated by physical exercise, Ajut Mario Sàlvia i Ferret 2014, lnstitut d’Estudis Catalans; SAF2016‐77703, MINECO and ERDF; 2017-SGR-106, AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Mechanisms of monomeric C Reactive Protein inducing neurodegeneration

  • García-Lara, Elisa
  • Aguirre Infantes, Samuel
  • Clotet Perarnau, Núria
  • Corpas, Rubén
  • Slevin, Mark
  • Sanfeliu, Coral
Trabajo presentado en el FENS Regional Meeting, celebrado en Belgrado (Sebia), del 10 al 13 de julio de 2019, AIM: Neuroinflammation derived from ischemic damage increases the risk of both vascular dementia and Alzheimer¿s disease (AD). The monomeric C- reactive protein (mCRP) formed in the dissociation of the pentraxin CRP within the extracellular matrix of ischemic tissue, may be a causative link between stroke-associated inflammation and memory loss. We aimed to investigate the mechanism underlying neuroinflammation and loss of neuroplasticity induced by mCRP. METHODS: We used our established in vivo model of dementia by bilateral hippocampus injection of mCRP in C57BL/6j mice. Transgenic AD mice 5XFAD were used for comparison. Cell lines of microglia BV2 and HMC3 and neuroblastoma SH-SY5Y were treated with mCRP or CRP. Microglial cells were also treated with lipopolysaccharide. We assayed hippocampus tissue and cell culture extracts for gene expression and protein levels in a search of changes underlying neuroinflammation, neuroplasticity loss and neurodegeneration. RESULTS: In vivo treatment with mCRP induced long-term loss of learning and memory, analyzed up to 6 months. First molecular results revealed lower activation of signaling pathways related to plasticity early genes Arc and Egr1 in mCRP mice. Main changes in 5XFAD were related to oxidative stress and gliosis markers. A main effect on protein processing induced by mCRP was hyperphosphorylation of tau in AD-associated pathogenic residues such as Ser202 and Ser396. We are analyzing the protective effects of anti-inflammatory agents. CONCLUSIONS: Characterizing the mechanisms of mCRP-induced dementia might contribute to fight against AD incidence in the elderly., EU-COP 2014-2020, CRP-SAD, ID: P_37_674, MySMIS code: 103432, contract: 51/05.09.2016; SAF2016‐77703, MINECO and ERDF; 2017-SGR-106, AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Mechanisms of neuroprotection of soluble epoxide hydrolase enzyme inhibition in Alzheimer's disease models

  • Corpas, Rubén
  • Clotet Perarnau, Núria
  • Aguirre Infantes, Samuel
  • García-Lara, Elisa
  • Slevin, Mark
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Vázquez, Santiago
  • Suñol, Cristina
  • Pallàs, Mercè
  • Sanfeliu, Coral
Trabajo presentado en el FENS Regional Meeting, celebrado en Belgrado (Sebia), del 10 al 13 de julio de 2019, Aim: Chronic neuroinflammation associated with aging contributes to the onset and progression of Alzheimer’s disease (AD). Epoxyeicosatrienoic acids (EETs) are endogenous mediators that have several protective functions including antiinflammatory effects. EETs beneficial effects diminish when the enzyme soluble epoxide hydrolase (sEH) metabolizes them to the corresponding dihydroxyeicosatrienoic acids. Previous results showed that sEH inhibition mitigates cognitive impairment and AD-like brain pathology in SAMP8 and 5XFAD mouse models of senescence and AD, respectively. Here we investigate the underlying mechanisms of neuroinflammation and proteostasis changes related to cognitive loss and its neuroprotection by sEH inhibitors. Methods: We used the known sEH inhibitor TPPU and the compound newly synthesized UB-EV-52. sEH inhibitors were administered through drinking water in the 5XFAD transgenic AD mouse models. In in vitro experiments, they were added to the media of microglia cell lines BV2 and HCM3, and neuroblastoma SH-SY5Y, previously treated with lipopolysaccharide or monomeric C- reactive protein as proinflammatory stimulus. As endpoints we analyzed inflammatory and survival pathways, and changes in proteostasis. Results: Our findings confirmed the beneficial effects of sEH inhibition, reducing the cognitive impairment, increase of proteolytic mechanism against aberrant proteins with decline of Aβ and tau pathology, and decrease of inflammatory markers that suggests a protection against inflammaging. Moreover, UB-EV-52 agent showed higher inhibitory potency than TPPU and no cytotoxicity. Conclusion: These results reinforce sEH as promising pharmacological target to fight against AD and other brain diseases that might be triggered by inflammaging processes, SAF2016‐77703, MINECO and ERDF; EU-COP 2014-2020, CRP-SAD, ID: P_37_674, MySMIS code: 103432, contract: 51/05.09.2016; 2017-SGR-106, AGAUR; Caixaimpuls 2018.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Monomeric C-Reactive protein aggravates secondary degeneration after intracerebral haemorrhagic stroke and may function as a sensor for systemic inflammation

  • Slevin, Mark
  • García-Lara, Elisa
  • Capitanescu, Bogdan
  • Sanfeliu, Coral
  • Zeinolabediny, Yasmin
  • AlBaradie, Raid
  • Olah, Peter
  • Guo, Baoqiang
  • Pirici, Daniel
  • Napoli, Mario Di
  • Popa-Wagner, Aurel
Background: We previously identified increased tissue localization of monomeric C-reactive protein (mCRP) in the infarcted cortical brain tissue of patients following ischaemic stroke. Here, we investigated the relationship of mCRP expression in haemorrhagic stroke, and additionally examined the capacity of mCRP to travel to or appear at other locations within the brain that might account for later chronic neuroinflammatory or neurodegenerative effects. Methods: Immunohistochemistry was performed on Formalin-fixed, paraffin-embedded archived brain tissue blocks obtained at autopsy from stroke patients and age-matched controls. We modelled mCRP migration into the brain after haemorrhagic stroke by infusing mCRP (3.5 µg) into the hippocampus of mice and localized mCRP with histological and immunohistochemistry methods. Results: On human tissue in the early stages of haemorrhage, there was no staining of mCRP. However, with increasing post-stroke survival time, mCRP immunostaining was associated with some parenchymal brain cells, some stroke-affected neurons in the surrounding areas and the lumen of large blood vessels as well as brain capillaries. Further from the peri-haematoma region, however, mCRP was detected in the lumen of micro-vessels expressing aquaporin 4 (AQP4). In the hypothalamus, we detected clusters of neurons loaded with mCRP along with scattered lipofuscin-like deposits. In the peri-haematoma region of patients, mCRP was abundantly seen adjacent to AQP4 immunoreactivity. When we stereotactically injected mCRP into the hippocampus of mice, we also observed strong expression in distant neurones of the hypothalamus as well as cortical capillaries. Conclusions: mCRP is abundantly expressed in the brain after haemorrhagic stroke, directly impacting the pathophysiological development of the haematoma. In addition, it may have indirect effects, where the microcirculatory system appears to be able to carry it throughout the cortex as far as the hypothalamus, allowing for long-distance effects and damage through its capacity to induce inflammation and degenerate neuronal perivascular compartments., This work was supported by a grant of the Romanian National Authority for Science Research and Innovation, CNCS—UEFISCDI, project number TE-41/2020 and from a grant from the Competitiveness Operational Programme 2014-2020: C-reactive protein therapy for stroke-associated dementia: ID_P_37_674, My SMIS code: 103432 contract 51/05.09.2016, and also and a grant from the Spanish Ministry of Science and Innovation SAF2016-77703 to CS. This research was also supported by the Stroke Chair-(project number R-1441-164)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bicyclic alfa-iminophosphonates as highly affinity imidazoline I2 receptor ligands for Alzheimer’s Disease

  • Abás, Sònia
  • Rodríguez Arévalo, Sergio
  • Bagán, Andrea
  • Griñán-Ferré, Christian
  • Vasilopoulou, Foteini
  • Brocos Mosquera, Iria
  • Muguruza, Carolina
  • Pérez, Belén
  • Molins, Elies
  • Luque, F. Javier
  • Pérez Lozano, Pilar
  • Jonghe, Steven de
  • Daelemans, Dirk
  • Naesens, Lieve
  • Brea, José Manuel
  • Loza, María Isabel
  • Hernández Hernández, Elena
  • García-Sevilla, Jesús Andrés
  • García Fuster, M. Julia
  • Radan, Milica
  • Djikic, Teodora
  • Nikolic, Katarina
  • Pallàs, Mercè
  • Callado, Luis F.
  • Escolano, Carmen
: Imidazoline I2 receptors (I2-IR), widely distributed in the CNS and altered in patients that suffer from neurodegenerative disorders, are orphans from a structural point of view, and new I2-IR ligands are urgently required for improving their pharmacological characterization. We report the synthesis and three-dimensional quantitative structure−activity relationship (3D-QSAR) studies of a new family of bicyclic α-iminophosphonates endowed with relevant affinities for human brain I2-IR. Acute treatment in mice with a selected compound significantly decreased Fas-associated protein with death domain (FADD) in the hippocampus, a key signaling mediator of neuroprotective actions. Additionally, in vivo studies in the familial Alzheimer’s disease 5xFAD murine model revealed beneficial effects in behavior and cognition. These results are supported by changes in molecular pathways related to cognitive decline and Alzheimer’s disease. Therefore, bicyclic α-iminophosphonates are tools that may open new therapeutic avenues for I2-IR, particularly for unmet neurodegenerative conditions., We strongly acknowledge the advice of Dr Andrés G. Fernández (our mentor in the CaixaImpulse 2018 program) for unvaluable advice. This study was supported by the Ministerio de Economía y Competitividad of Spain (SAF2016-3307) and the Basque Government (IT1211- 19). The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434) under agreement CI18-00002. This activity has received funding from the European Institute of Innovation and Technology (EIT). This body of the European Union receives support from the European Union’s Horizon 2020 research and innovation programme. C.G.-F, F. V., C. E., S. R-A., A. B. and M. P. belong to 2017SGR106 (Generalitat de Catalunya). J. A. G.-S. is a member emeritus of the Institut d’Estudis Catalans. Financial support was provided for F. V. (University of Barcelona, APIF_2017), S. R.-A. (Generalitat de Catalunya, 2018FI_B_00227), A. B. (Institute of Biomedicine UB_2018), C. M. (Marie Sklodowska-Curie Actions Individual Fellowships H2020-MSCA-IF-2016, ID747487), and E. H.-H. (Consejería de Innovación, Investigación y Turismo del Gobierno de las Islas Baleares y del Fondo Social Europeo, FPI/2102/2018). MR, TD and KN kindly acknowledge Ministry of Science and Technological Development of the Republic of Serbia, Project Contract No. 172033, and HORISON2020- COST-Action CA18133 ERNEST: European Research Network on Signal Transduction., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer's Disease

  • Griñán-Ferré, Christian
  • Codony, Sandra
  • Pujol, Eugènia
  • Yang, Jun
  • Leiva, Rosana
  • Escolano, Carmen
  • Puigoriol-Illamola, Dolors
  • Companys-Alemany, Júlia
  • Corpas, Rubén
  • Sanfeliu, Coral
  • Pérez, Belén
  • Loza, María Isabel
  • Brea, José Manuel
  • Morisseau, Christophe
  • Hammock, Bruce D.
  • Vázquez, Santiago
  • Pallàs, Mercè
  • Galdeano, Carles
The inhibition of the enzyme soluble epoxide hydrolase (sEH) has demonstrated clinical therapeutic effects in several peripheral inflammatory-related diseases, with 3 compounds in clinical trials. However, the role of this enzyme in the neuroinflammation process has been largely neglected. Herein, we disclose the pharmacological validation of sEH as a novel target for the treatment of Alzheimer's disease (AD). Evaluation of cognitive impairment and pathological hallmarks were used in 2 models of age-related cognitive decline and AD using 3 structurally different and potent sEH inhibitors as chemical probes. sEH is upregulated in brains from AD patients. Our findings supported the beneficial effects of central sEH inhibition, regarding reducing cognitive impairment, neuroinflammation, tau hyperphosphorylation pathology, and the number of amyloid plaques. This study suggests that inhibition of inflammation in the brain by targeting sEH is a relevant therapeutic strategy for AD., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) (Projects SAF2017-82771, SAF2016-77703, Fundació La Caixa (project CI18-00002) and SAF2015-68749) and Generalitat de Catalunya (2017 SGR 106). S.C. and E.P. thank the Universitat de Barcelona and the Institute of Biomedicine of the Universitat de Barcelona (IBUB), respectively, for PhD grants. R.L. and D.P.-I. thank the Ministerio de Educación, Cultura y Deporte for PhD grants (FPU program). We would also like to thank Xunta de Galicia (ED431C 2018/21) and Ministerio de Economía, Industria y Competitividad (Innopharma Project) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER). This study was also supported, in part, by grants from the National Institute of Environmental Health Sciences (NIEHS), the RIVER Award, NIEHS/R35 ES030443, and NIEHS Superfund Research Program P42 ES004699. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Antibody protection against long-term memory loss induced by monomeric c-reactive protein in a mouse model of dementia

  • García-Lara, Elisa
  • Aguirre Infantes, Samuel
  • Clotet Perarnau, Núria
  • Sawkulycz, Xenia
  • Bartra Cabré, Clara
  • Almenara-Fuentes, Lidia
  • Suñol, Cristina
  • Corpas, Rubén
  • Olah, Peter
  • Tripon, Florin
  • Crauciuc, Andrei
  • Slevin, Mark
  • Sanfeliu, Coral
Monomeric C-reactive protein (mCRP), the activated isoform of CRP, induces tissue damage in a range of inflammatory pathologies. Its detection in infarcted human brain tissue and its experimentally proven ability to promote dementia with Alzheimer’s disease (AD) traits at 4 weeks after intrahippocampal injection in mice have suggested that it may contribute to the development of AD after cerebrovascular injury. Here, we showed that a single hippocampal administration of mCRP in mice induced memory loss, lasting at least 6 months, along with neurodegenerative changes detected by increased levels of hyperphosphorylated tau protein and a decrease of the neuroplasticity marker Egr1. Furthermore, co-treatment with the monoclonal antibody 8C10 specific for mCRP showed that long-term memory loss and tau pathology were entirely avoided by early blockade of mCRP. Notably, 8C10 mitigated Egr1 decrease in the mouse hippocampus. 8C10 also protected against mCRP-induced inflammatory pathways in a microglial cell line, as shown by the prevention of increased generation of nitric oxide. Additional in vivo and in vitro neuroprotective testing with the anti-inflammatory agent TPPU, an inhibitor of the soluble epoxide hydrolase enzyme, confirmed the predominant involvement of neuroinflammatory processes in the dementia induced by mCRP. Therefore, locally deposited mCRP in the infarcted brain may be a novel biomarker for AD prognosis, and its antibody blockade opens up therapeutic opportunities for reducing post-stroke AD risk., This research was funded by the European Competitiveness Operational Programme 2014– 2020, C-Reactive protein therapy for stroke-associated dementia, ID P_37_674, MySMIS code: 103432, contract 51/05.09.2016; Spanish MINECO and European Regional Development Fund, grant number SAF2016-77703; Spanish MCINN, grant number PID2019-106285RB; Catalan Autonomous Government AGAUR, grant number 2017-SGR-106; the CERCA Programme/Generalitat de Catalunya. R.C was supported by a post-doctoral research contract of the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglial hyperreactivity evolved to immunosuppression in the hippocampus of a mouse model of accelerated aging and Alzheimer’s Disease traits

  • Molina-Martínez, Patricia
  • Corpas, Rubén
  • García-Lara, Elisa
  • Cosín-Tomás, Marta
  • Cristòfol, Rosa
  • Kaliman, Perla
  • Solà, Carme
  • Molinuevo, José Luis
  • Sánchez-Valle, Raquel
  • Antonell, Anna
  • Lladó, Albert
  • Sanfeliu, Coral
Neuroinflammation is a risk factor for Alzheimer’s disease (AD). We sought to study the glial derangement in AD using diverse experimental models and human brain tissue. Besides classical pro-inflammatory cytokines, we analyzed chitinase 3 like 1 (CHI3L1 or YKL40) and triggering receptor expressed on myeloid cells 2 (TREM2) that are increasingly being associated with astrogliosis and microgliosis in AD, respectively. The SAMP8 mouse model of accelerated aging and AD traits showed elevated pro-inflammatory cytokines and activated microglia phenotype. Furthermore, 6-month-old SAMP8 showed an exacerbated inflammatory response to peripheral lipopolysaccharide in the hippocampus and null responsiveness at the advanced age (for this strain) of 12 months., This research was funded by Spanish MINECO and European Regional Development Fund, grant number SAF2016- 77703; Spanish MCINN, grant number PID2019-106285RB; Catalan Autonomous Government AGAUR, grant number 2017-SGR-106; Competitiveness Operational Programme 2014-2020, C-Reactive protein therapy for stroke-associated dementia, ID P_37_674, MySMIS code: 103432, contract 51/05.09.2016; and the CERCA Programme/Generalitat de Catalunya. RCo was supported by a post-doctoral research contract of the Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. AL (PERIS SLT008/18/00061) received funding from Departament de Salut de la Generalitat de Catalunya. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms

  • Sarroca, Sara
  • Gatius, Alaó
  • Rodríguez-Farré, Eduard
  • Vilchez, David
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
  • Sanfeliu, Coral
  • Corpas, Rubén
Cumulative evidence indicates that excessive consumption of calories from saturated fat contributes to the development of Alzheimer's disease (AD). Here, we assess the triggering and progression of AD pathology induced by a high-fat diet (HFD), and the effects of resveratrol, a polyphenol found in common dietary sources with pleiotropic neuroprotective activities. Over 16 weeks, male wild type (WT) and AD transgenic 5XFAD mice were fed a control diet, HFD (60% kcal from fat), or HFD supplemented with 0.1% resveratrol. Resveratrol protected against HFD-induced memory loss in WT mice and prevented memory loss in 5XFAD mice. Resveratrol also reduced the amyloid burden aggravated by HFD in 5XFAD, and protected against HFD-induced tau pathology in both WT and 5XFAD strains. At the mechanistic level, resveratrol inhibited the HFD-increased amyloidogenic processing of the amyloid precursor protein in both strains; it also restored abnormal high levels in the proteolytic activity of the ubiquitin-proteasome system induced by HFD, suggesting the presence of a compensatory mechanism to counteract the accumulation of aberrant proteins. Thus, our data suggest that resveratrol can correct the harmful effects of HFD in the brain and may be a potential therapeutic agent against obesity-related disorders and AD pathology., This research was funded by Spanish MINECO and European Regional Development Fund (grant number SAF2016-77703-C2); Spanish MCINN (grant number PID2019-106285RB); Catalan Autonomous Government AGAUR (grant number 2017-SGR-106); and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Tesis doctoral (DoctoralThesis)

Implicación de la proteína C reactiva monomérica en el desarrollo de demencia de tipo Alzheimer: modelo experimental y posibles terapias

  • García-Lara, Elisa
Tesis doctoral presentada para lograr el título de Doctor en Biomedicina por la Universidad de Barcelona, Facultad de Medicina y Ciencias de la Salud.--2021-02-19.--Excelente, La neuroinflamación sostenida es un factor de riesgo de enfermedades relacionadas con la edad, incluidas las lesiones cerebrovasculares y la enfermedad de Alzheimer (EA). De hecho, los procesos inflamatorios se consideran cada vez más los culpables de la fragilidad y la enfermedad de la población envejecida. Como resultado, se ha intensificado la búsqueda de biomarcadores inflamatorios fiables y objetivos de intervención para combatir la demencia y otras enfermedades discapacitantes. Cada año se registran cerca de 8 millones de nuevos casos de demencia, y se estima que, para el 2050, la demencia afecte a 150 millones de personas. La enfermedad de Alzheimer (EA) es la más prevalente de las demencias, suponiendo entre un 60 y un 70% de todos los casos de demencia. Esta enfermedad se caracteriza por la pérdida cognitiva y de memoria, junto a la presentación de síntomas conductuales y psicológicos asociados a la demencia (BPSD) que disminuyen de manera drástica la calidad de vida del paciente y sus cuidadores. La neuropatología de la EA se caracteriza por el depósito proteico del péptido amiloide y tau hiperfosforilada que, eventualmente, desembocan en la agregación de placas seniles y ovillos neurofibrilares. Esta patología además, suele ir acompañada de neuroinflamación, aumento del extrés oxidativo y disfunción mitocondrial, alteración neurovascular, pérdida sináptica y neurodegeneración. Actualmente no existe cura para el Alzheimer, por ello, nuevas terapias que aborden su prevención o presenten nuevas vías de investigación son imprescindibles. En esta tesis se ha pretendido evaluar la contribución de la proteína monomérica C-reactiva al desarrollo de demencia de tipo EA. La proteína C-Reactiva (CRP) es una pentraxina, secretada por el hígado en respuesta a la inflamación y ampliamente conocida por ser un marcador de procesos inflamatorios. Así cuando el pentaméro que es la CRP se une a las membranas de los tejidos dañados, esta se disocia dando lugar a sus subunidades monoméricas, altamente pro-inflamatorias y poco solubles, que quedan depositadas de manera crónica en la matriz extracelular del tejido afectado. La proteína monomérica C-reactiva es, por lo tanto, una de las subunidades monoméricas de la CRP. Así, la mCRP depositada en la matriz extracelular del tejido dañado favorece un ambiente proinflamatorio crónico que, sumado a su alta capacidad angiogénica favorece el agravamiento de la enfermedad. Estudios recientes han confirmado la presencia de mCRP en el tejido cerebral de enfermos de EA, así como la capacidad de las placas amiloides para disociar CRP generando mCRP. Asimismo, se ha demostrado cómo mCRP favorece la fosforilización de tau in vitro y cómo la tau fosforilada colocaliza a nivel intraneuronal con mCRP en cerebros de pacientes de EA., Por otra parte, estudios previos de nuestro grupo de investigación desmotraron que la mCRP inyectada en el hipocampo de ratones inducía pérdida de memoria después de 4 semanas, así como otros rasgos de la EA, como patología amiloide y de tau en neuronas del hipocampo y áreas corticales. Estos estudios también han confirmado a mCRP como un posible vínculo entre el ictus y el posterior desarrollo de demencia que aparece en un tercio de los casos de accidente cerebrovascular. Así, la hipótesis en que se basa esta tesis es que la mCRP, la forma activada de la CRP, contribuye al desarrollo y progresión de la enfermedad de EA. Con el fin de probar esta hipotésis, desarrollamos un modelo de ratón de demencia inducido mediante la infusión bilateral de mCRP en el hipocampo de los ratones. Los animales fueron evaluados tras 1, 3 y 6 meses de tratamiento con mCRP con el fin de caracterizar la pérdida cognitiva y de BPSD de este modelo, así como la neuropatología adyacente. Posteriormente se realizó otro estudio en el que se utilizó el modelo de demencia inducido por mCRP para evaluar si el tratamiento con un anticuerpo monoclonal anti-mCRP era capaz de bloquear los efectos patológicos inducidos por esta a 1, 3 y 6 meses de tratamiento. Asimismo, tambien evaluamos los posibles efectos protectores del antiinflamatorio TPPU en nuestro modelo de demencia por mCRP a 1 mes de tratamiento. Nuestros estudios in vivo fueron complementados por estudios in vitro en los que evaluamos la respuesta de la línea de microglía BV2 ante mCRP, así como la posible inhibición de los efectos proinflamatorios de mCRP mediante el anticuerpo monoclonal anti-mCRP y el antiinflmatorio TPPU. Nuestros resultados revelaron que: -La inyección estereotáxica bilateral de mCRP en el hipocampo de ratones adultos indujo pérdida cognitiva a 1, 3 y 6 meses de tratamiento, y aparición de BPSD a los 6 meses de tratamiento. -mCRP permaneció en el hipocampo de los ratones desde 1 mes hasta 6 meses después del tratamiento, diseminándose de manera parcial hasta el córtex y el hipocampo. -mCRP indujo, en los lugares donde se deposita; neuroinflamación y aparición del péptido amiloide de manera local y fosforilación de tau y pérdida de la plasticidad de manera generalizada en el hipocampo. -Los efectos deletereos inducidos por mCRP fueron bloqueados por el anticuerpo monoclonal anti-mCRP tanto a nivel cognitivo y conductual como a nivel molecular. -El antiinflamatorio TPPU inhibió la pérdida cognitiva inducida por mCRP en nuestro modelo de ratón tras un mes de tratamiento. -mCRP indujo inflamación microglial que fue bloqueada tanto por el anticuerpo monoclonal anti-mCRP como por el antiinflamatorio TPPU. Así, en esta tesis se demuestra la implicación de la proteína mCRP en el desarrollo de demencia de tipo EA y se presenta un nuevo modelo de demencia por inyección de mCRP, así como posibles tratamientos que bloqueen la actividad deleterea de mCRP disminuyendo sus efectos adversos en la EA. Finalmente, el bloqueo específico de mCRP es una terapia prometedora para reducir la neurodegeneración después de una lesión cerebrovascular y el desarrollo de EA, la forma más común de demencia en la población anciana. Además, la mCRP puede ser un biomarcador útil del pronóstico de procesos neurodegenerativos asociados a la neuroinflamación, puediendo detectarse mediante técnicas no invasivas. Los avances en la detección de mCRP y los enfoques terapéuticos contra esta presentan nuevas perspectivas en la lucha contra las condiciones patológicas afectadas por la interacción dañina entre mCRP y células y tejidos.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

  • Codony, Sandra
  • Calvó-Tusell, Carla
  • Valverde, Elena
  • Osuna, Sílvia
  • Morisseau, Christophe
  • Loza, M. Isabel
  • Brea, José
  • Pérez, Concepción
  • Rodríguez-Franco, María Isabel
  • Pizarro-Delgado, Javier
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Vázquez-Carrera, Manuel
  • Hammock, Bruce D.
  • Feixas, Ferran
  • Vázquez, Santiago
The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs., This work was funded by the Spanish Ministerio de Economía, Industria y Competitividad (grants SAF2017-82771-R to S.V., RTI2018-093999-B-100 to M. V.-C., RTI2018-093955-B-C21 to M.I.R.-F., SAF2016-77703-C2 to M.P. and C.S., PGC2018- 102192-B-I00 to S.O. and RTI2018-101032-J-I00 to F.F.), the Spain EIT Health (Proof of concept 2016), the European Regional Development Fund (ERDF), the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21), the Fundació Bosch i Gimpera, Universitat de Barcelona (F2I grant), the Generalitat de Catalunya (2017 SGR 106, 2017 SGR 124 and 2017 SGR 1707), the European Research Council (ERC-2015-StG-679001-Net- MoDEzyme to S.O.), and the European Community (MSCA-IF- 2014-EF-661160-MetAccembly to F.F.). S.C. and E.V. acknowledge the PhD fellowships from the Universitat de Barcelona (APIF grant) and the Institute of Biomedicine of the University of Barcelona (IBUB), respectively. Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health., Peer reviewed